| Objective Lupus nephritis(LN) is the most common clinical situation of systemic lupus erythematosus (SLE) , with kidney pathological biopsy showing that almost all SLE patients have pathological damage with different degrees. In addition, impaired degree of kidney is an important agent to influence the prognosis of SLE. The purpose of the article is to explore the efficacy and safety of a course of intermittent low-dosage intravenous (IV) Cyclophosphamide (CTX) for chronic renal insufficiency due to lupus nephritis. So that we are likely to find a new method to treat chronic renal insufficiency due to lupus nephritis and improve the life quality of SLE patients.Methods Of 331 patients with SLE in our hospital between the year 2000 and 2007, 12 patients with chronic renal insufficiency with azotemia due to lupus nephritis received intermittent low-dosage Cyclophosphamide therapy. CTX was given 200 to 400mg per 2 to 4weeks in this course, and the dosage was regulated according to the improvement of the disease. The follow-up time was for 2 month-5 years. We observed clinical outcomes and laboratory changes.Results During the follow-up period, SLEDAI significantly decreased in all cases. Renal function was improved in varying degrees, with serum creatinine decreased to normal in 9 cases and partially improved in another 3 cases which were still in azotemia. As far as adverse reactions were concerned, No obvious side effects occurred.Conclusion The treatment of this course in a short period is effective and secure. But it is necessary to perform clinical obseavations on large samples and long-term follow-up to assess renal function so that we can determine its effects in the long run..
|
PDF Full Text Request